October 7, 2024 – Actylis, a prominent provider of specialty ingredients for the life sciences and advanced technology sectors, has announced the acquisition of Pharm-Rx, a New Jersey-based supplier of value-added ingredients for the vitamin, mineral, supplement (VMS), and pharmaceutical industries. This strategic acquisition aims to enhance Actylis’ product offerings and expand its services for nutrition and over-the-counter (OTC) pharmaceutical customers.
Strategic Expansion
The acquisition of Pharm-Rx will bolster Actylis’ ability to deliver a broader range of specialty ingredients and improve its solutions for clients in the VMS and pharmaceutical sectors. Scott Thomson, CEO of Actylis, emphasized the importance of the acquisition as part of the company’s growth strategy. “This is a significant milestone for Actylis. Pharm-Rx’s strong team and expertise allow us to offer even greater value to our customers through an expanded portfolio and enhanced capabilities,” Thomson stated.
Pharm-Rx, which has operated for over 30 years, is recognized for its ability to source difficult-to-find active ingredients from global manufacturers and address complex regulatory and logistical challenges. Its customer-centric approach has earned the company a solid reputation within the VMS and pharmaceutical industries.
Leadership and Integration
As part of the acquisition, Mark Bostel, current President & Head of Business Development at Pharm-Rx, will take on the role of President, of Global Nutrition and OTC at Actylis. Bostel will oversee both Pharm-Rx and Actylis’ Nutrition and OTC businesses. He expressed optimism about the partnership, noting that it will allow both companies to expand their client base and product offerings. “Pharm-Rx and Actylis complement each other well, positioning us to serve our markets better and unlock new opportunities,” Bostel said.
Pharm-Rx will continue to operate under its existing brand and management team, including key executives Carlos Doussinague and Ann Smith.
The acquisition aligns with Actylis’ strategy to expand its global reach and improve its service offerings for the VMS and pharmaceutical markets. By integrating Pharm-Rx’s expertise, Actylis aims to strengthen its supplier partnerships and deliver more comprehensive solutions to its customers.
The financial details of the acquisition were not disclosed. UB Greensfelder LLP advised Actylis, while Alantra, Adams, and Reese LLP represented Pharm-Rx.
